Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Radotinib HCl
DRUG
3 trials
Sponsors
Il-Yang Pharm Co. Ltd.
, Il-Yang Pharm. Co., Ltd.
Conditions
CML - Philadelphia Chromosome
CML, Chronic Phase
CML, Refractory
Chronic Myeloid Leukemia, Chronic Phase
Drug Kinetics
Treatment of Parkinson’s disease (PD)
Phase 1
Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib
Completed
NCT06461078
Il-Yang Pharm. Co., Ltd.
Drug Kinetics
Start: 2024-07-22
End: 2025-04-28
Updated: 2025-04-30
Phase 2
A randomized double-blind placebo-controlled multicentre study to assess safety, tolerability, pharmacokinetics and efficacy of Radotinib in Parkinson’s disease.
Active, not recruiting
CTIS2024-516549-37-00
Il-Yang Pharm Co. Ltd.
Treatment of Parkinson’s disease (PD)
Start: 2021-04-12
Target: 40
Updated: 2025-10-10
Phase 3
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Recruiting
NCT03459534
Il-Yang Pharm. Co., Ltd.
Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML - Philadelphia Chromosome +1
Start: 2018-06-25
End: 2028-06-30
Target: 173
Updated: 2026-09-03
Related Papers
Clinical pharmacokinetic characteristics and the food effect of radotinib.
2026-03-27